Numerous clinical trials unequivocally demonstrate the kidney protective effects of SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin) in patients with CKD with or without type 2 DM and any degree of albuminuria [36, 43]. The gene discussed is SLC5A2; the disease is chronic kidney disease.